Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarction–Dilated Cardiomyopathy
暂无分享,去创建一个
[1] A. Dahan,et al. The erythropoietin analog ARA 290 for treatment of sarcoidosis-induced chronic neuropathic pain , 2013 .
[2] A. Dahan,et al. Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study , 2012, Molecular medicine.
[3] V. Fuster,et al. Contemporary medical management of systolic heart failure. , 2012, Circulation journal : official journal of the Japanese Circulation Society.
[4] P. Shah,et al. Chronic Heart Failure , 2011, American journal of cardiovascular drugs : drugs, devices, and other interventions.
[5] E. Lakatta,et al. A Small Nonerythropoietic Helix B Surface Peptide Based upon Erythropoietin Structure Is Cardioprotective against Ischemic Myocardial Damage , 2011, Molecular medicine.
[6] G. Lippi,et al. Thrombotic complications of erythropoiesis-stimulating agents. , 2010, Seminars in thrombosis and hemostasis.
[7] M. Segal,et al. Induction of nitric oxide by erythropoietin is mediated by the {beta} common receptor and requires interaction with VEGF receptor 2. , 2010, Blood.
[8] C. Stefanadis,et al. Is there a role for erythropoietin in cardiovascular disease? , 2010, Expert opinion on biological therapy.
[9] H. Sakagami,et al. Effect of erythropoietin on angiogenesis with the increased adhesion of platelets to the microvessels in the hind-limb ischemia model in mice. , 2010, Journal of pharmacological sciences.
[10] R. de Caterina,et al. Erythropoietin protects myocardin-expressing cardiac stem cells against cytotoxicity of tumor necrosis factor-alpha. , 2009, Experimental cell research.
[11] E. Lakatta,et al. Therapeutic Efficacy of a Combination of a β1-Adrenoreceptor (AR) Blocker and β2-AR Agonist in a Rat Model of Postmyocardial Infarction Dilated Heart Failure Exceeds That of a β1-AR Blocker plus Angiotensin-Converting Enzyme Inhibitor , 2009, Journal of Pharmacology and Experimental Therapeutics.
[12] A. Cerami,et al. Erythropoietin‐mediated tissue protection: reducing collateral damage from the primary injury response , 2008, Journal of internal medicine.
[13] Michael A. Yamin,et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin , 2008, Proceedings of the National Academy of Sciences.
[14] D. Yellon,et al. Erythropoietin: ready for prime-time cardioprotection. , 2008, Trends in pharmacological sciences.
[15] M. Arcasoy. The non‐haematopoietic biological effects of erythropoietin , 2008, British journal of haematology.
[16] K. Abel,et al. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO) , 2008, Thrombosis and Haemostasis.
[17] R. Latini,et al. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? , 2008, Heart Failure Reviews.
[18] P. Galajda,et al. Soluble P-Selectin During a Single Hemodialysis Session in Patients With Chronic Renal Failure and Erythropoietin Treatment , 2007, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.
[19] M. Guglin,et al. Erythropoietin in Cardiovascular Diseases Recent Patents on Cardiovascular Drug Discovery , 2007 .
[20] A. Voors,et al. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. , 2006, Journal of the American College of Cardiology.
[21] A. Cerami,et al. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. , 2006, Kidney international.
[22] E. Lakatta,et al. Pharmacological Stimulation of β 2-adrenergic Receptors (β 2AR) Enhances Therapeutic Effectiveness of β 1AR Blockade in Rodent Dilated Ischemic Cardiomyopathy , 2005, Heart Failure Reviews.
[23] A. Berger,et al. Changes in thrombopoiesis and platelet reactivity in extremely low birth weight infants undergoing erythropoietin therapy for treatment of anaemia of prematurity , 2004, Thrombosis and Haemostasis.
[24] E. Lakatta,et al. Pharmacological stimulation of beta2-adrenergic receptors (beta2AR) enhances therapeutic effectiveness of beta1AR blockade in rodent dilated ischemic cardiomyopathy. , 2005, Heart Failure Reviews.
[25] P. Ghezzi,et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] M. Bogoyevitch. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. , 2004, Cardiovascular research.
[27] Z. Erbayraktar,et al. Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.
[28] C. Noguchi,et al. Erythropoietin Stimulates Proliferation and Interferes with Differentiation of Myoblasts* , 2000, The Journal of Biological Chemistry.
[29] H. Eichler,et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. , 2000, Blood.
[30] N. Vaziri,et al. Mechanism of erythropoietin-induced hypertension. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] D. Nisato,et al. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. , 1999, Cardiovascular research.
[32] R. Wolf,et al. Erythropoietin Administration Increases Production and Reactivity of Platelets in Dogs , 1997, Thrombosis and Haemostasis.
[33] P. Pagel,et al. The Effects of Isoflurane and Halothane on Left Ventricular Afterload in Dogs with Dilated Cardiomyopathy , 1997, Anesthesia and analgesia.
[34] R. Wolf,et al. Erythropoietin Potentiates Thrombus Development in a Canine Arterio-Venous Shunt Model , 1997, Thrombosis and Haemostasis.
[35] E. Thibout,et al. Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling. , 1997, Circulation.
[36] P. Anversa,et al. Myocyte cellular hypertrophy and hyperplasia contribute to ventricular wall remodeling in anemia-induced cardiac hypertrophy in rats. , 1992, The American journal of pathology.
[37] A. Heidland,et al. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. , 1988, American journal of nephrology.
[38] J. Bahlmann,et al. Effect of treatment with recombinant human erythropoietin on peripheral hemodynamics and oxygenation. , 1988, Contributions to nephrology.
[39] M. Pfeffer,et al. Hemodynamic benefits and prolonged survival with long-term captopril therapy in rats with myocardial infarction and heart failure. , 1987, Circulation.
[40] M. Pfeffer,et al. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. , 1985, Circulation.